FDA Inspection 1172425 — Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited — FEI 3005757050

The FDA completed an inspection of Glenmark Pharmaceuticals Limited on June 22, 2022 in Solan. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 6 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
June 22, 2022
Fiscal Year
2022
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Solan (India)

Citations

IDCFRDescription
110521 CFR 211.22(d)Procedures not in writing, fully followed
121321 CFR 211.67(a)Cleaning / Sanitizing / Maintenance
127021 CFR 211.68(b)input/output verification
136121 CFR 211.100(a)Absence of Written Procedures
202721 CFR 211.192Investigations of discrepancies, failures
891121 CFR 314.81(b)(1)(ii)Failure to meet specifications